CoChat

Discovery and characterization of taspoglutide, a novel analogue of human glucagon‐like peptide‐1, engineered for sustained therapeutic activity in type 2 diabetes

Dong, J. Z., Shen, Y., Zhang, J., Tsomaia, N., Mierke, D. F., Taylor, J. E. · 2011 · Diabetes, Obesity and Metabolism
Cited by 38

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Aim: Glucagon‐like peptide‐1 (GLP‐1) receptor agonists for the treatment of type 2 diabetes are administered by daily injection because of short plasma half‐lives, which result partly from the biochemical instability of these peptides. There is a medical need for GLP‐1 analogues that can be administered less frequently for patient convenience. Methods: We synthesized a series of human GLP‐1 (hGLP‐1(7‐36)NH 2 ) derivatives containing α ‐aminoisobutyric acid (Aib) substitutions, analysed their enzymatic stabilities and evaluated their secondary structures using circular dichroism (CD) and nuclear magnetic resonance (NMR). Results: Plasma stability experiments showed that only the analogue containing Aib substitutions in both the N‐terminus (position 8) and the C‐terminus (position 35), [Aib 8,35 ]hGLP‐1(7‐36)NH 2 (BIM‐51077), was fully resistant to enzymatic cleavage. Incubation with human plasma kallikrein or plasmin confirmed that the Aib substitution at position 35 prevented protease cleavage around this residue, which contributes to the significantly enhanced plasma stability and increased plasma half‐life. CD revealed increased C‐terminal α ‐helicity in Aib 35 ‐substituted analogues compared with both hGLP‐1(7‐36)NH 2 and analogues containing only Aib 8 substitutions. Based on NMR studies, the secondary structure of BIM‐51077 is similar to hGLP‐1(7‐36)NH 2 with a slight increase in α ‐helicity in the C‐terminus. Compared with hGLP‐1(7‐36)NH 2 , BIM‐51077 had similar binding affinity for the human GLP‐1 receptor and activated this receptor with similar potency. Conclusions: We have discovered an Aib 8,35 ‐substituted analogue of native hGLP‐1(7‐36)NH 2 (BIM‐51077) that retains the structure of the native peptide, and has similar activity and enhanced stability. A sustained‐release formulation of this molecule (taspoglutide) is in phase‐3 clinical development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2010.01313.x

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 38

Metadata

Authors
Dong, J. Z., Shen, Y., Zhang, J., Tsomaia, N., Mierke, D. F., & Taylor, J. E.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2010-11-28
Volume
13
Issue
1
Pages
19-25
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W1966309593
Cited by
38
References
6
FWCI
1.98
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discovery and characterization of taspoglutide, a novel analogue of human glucagon‐like peptide‐1, engineered for sustained therapeutic activity in type 2 diabetes. https://app.cochat.ai/papers/10.1111/j.1463-1326.2010.01313.x
The paper
Dong, J. Z., Shen, Y., Zhang, J., Tsomaia, N., Mierke, D. F., & Taylor, J. E. (2011). Discovery and characterization of taspoglutide, a novel analogue of human glucagon‐like peptide‐1, engineered for sustained therapeutic activity in type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2010.01313.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.